<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-title-group><journal-title>Arthritis Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">ar2828</article-id><article-id pub-id-type="pmid">19818132</article-id><article-id pub-id-type="doi">10.1186/ar2828</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research article</subject></subj-group></article-categories><title-group><article-title>The <italic>ITGAV </italic>rs3738919 variant and susceptibility to rheumatoid arthritis in four Caucasian sample sets</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Hollis-Moffatt</surname><given-names>Jade E</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jade.hollis-moffatt@otago.ac.nz</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Rowley</surname><given-names>Kerry A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>kerry.rowley@otago.ac.nz</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Phipps-Green</surname><given-names>Amanda J</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mandy.phipps-green@otago.ac.nz</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Merriman</surname><given-names>Marilyn E</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>marilyn.merriman@otago.ac.nz</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Dalbeth</surname><given-names>Nicola</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>n.dalbeth@auckland.ac.nz</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Gow</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>PGow@middlemore.co.nz</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Harrison</surname><given-names>Andrew A</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>andrew.harrison@otago.ac.nz</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Highton</surname><given-names>John</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>john.highton@otago.ac.nz</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Jones</surname><given-names>Peter BB</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>peter.jones@qehealth.co.nz</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Stamp</surname><given-names>Lisa K</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>lisa.stamp@cdhb.govt.nz</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Harrison</surname><given-names>Pille</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>Pille.Harrison@ndorms.ox.ac.uk</email></contrib><contrib contrib-type="author" id="A12"><name><surname>Wordsworth</surname><given-names>B Paul</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>Paul.Wordsworth@ndm.ox.ac.uk</email></contrib><contrib contrib-type="author" id="A13"><name><surname>Merriman</surname><given-names>Tony R</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>tony.merriman@stonebow.otago.ac.nz</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Biochemistry, University of Otago, 710 Cumberland Street, Dunedin 9054, New Zealand</aff><aff id="I2"><label>2</label>Department of Medicine, University of Auckland, 2 Park Road, Auckland 1023, New Zealand</aff><aff id="I3"><label>3</label>Rheumatology, Middlemore Hospital, 100 Hospital Road, Auckland 2025, New Zealand</aff><aff id="I4"><label>4</label>Department of Medicine, University of Otago, 23A Mein Street, Wellington 6242, New Zealand</aff><aff id="I5"><label>5</label>Department of Medicine, University of Otago, 201 Great King Street, Dunedin 9016, New Zealand</aff><aff id="I6"><label>6</label>Department of Medicine, University of Otago, 2 Riccarton Avenue, Christchurch 8140, New Zealand</aff><aff id="I7"><label>7</label>Nuffield Department of Orthopaedics, Nuffield Orthopaedic Centre, Windmill Road, Oxford OX3 7LD, UK</aff><pub-date pub-type="ppub"><year>2009</year></pub-date><pub-date pub-type="epub"><day>9</day><month>10</month><year>2009</year></pub-date><volume>11</volume><issue>5</issue><fpage>R152</fpage><lpage>R152</lpage><history><date date-type="received"><day>18</day><month>5</month><year>2009</year></date><date date-type="rev-request"><day>15</day><month>6</month><year>2009</year></date><date date-type="rev-recd"><day>29</day><month>9</month><year>2009</year></date><date date-type="accepted"><day>9</day><month>10</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2009 Hollis-Moffatt et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Hollis-Moffatt et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://arthritis-research.com/content/11/5/R152"/><abstract><sec><title>Introduction</title><p>Angiogenesis is an important process in the development of destructive synovial pannus in rheumatoid arthritis (RA). The <italic>ITGAV </italic>+gene encodes a cell cycle-associated antigen, integrin &#x003b1;&#x003bd;&#x003b2; 3, which plays a role in RA angiogenesis. Previously, two independent studies identified an association between the major allele of the <italic>ITGAV </italic>single-nucleotide polymorphism (SNP) <italic>rs3738919 </italic>and RA. We therefore tested this association in an independent study using New Zealand (NZ) and Oxford (UK) RA case control samples.</p></sec><sec><title>Methods</title><p>We compared genotype frequencies in 740 NZ Caucasian RA patients and 553 controls genotyped for <italic>rs3738919</italic>, using a polymerase chain reaction-restriction fragment length polymorphism assay. A TaqMan genotyping SNP assay was used to type 713 Caucasian RA patients and 515 control samples from Oxford for the <italic>rs3738919 </italic>variant. Association of <italic>rs3738919 </italic>with RA was tested in these two sample sets using the chi-square goodness-of-fit test. The Mantel-Haenszel test was used to perform a meta-analysis, combining the genetic results from four independent Caucasian case control cohorts, consisting of 3,527 cases and 4,126 controls. Haplotype analysis was also performed using SNPs <italic>rs3911238</italic>, <italic>rs10174098 </italic>and <italic>rs3738919 </italic>in the Wellcome Trust Case Control Consortium, NZ and Oxford case control samples.</p></sec><sec><title>Results</title><p>We found no evidence for association between <italic>ITGAV </italic>and RA in either the NZ or Oxford sample set (odds ratio [OR] = 0.88, <italic>P</italic><sub><italic>allelic </italic></sub>= 0.11 and OR = 1.18, <italic>P</italic><sub><italic>allelic </italic></sub>= 0.07, respectively). Inclusion of these data in a meta-analysis (random effects) of four independent cohorts (3,527 cases and 4,126 controls) weakens support for the hypothesis that <italic>rs3738919 </italic>plays a role in the development of RA (OR<sub><italic>combined </italic></sub>= 0.92, 95% confidence interval 0.80 to 1.07; <italic>P </italic>= 0.29). No consistent haplotype associations were evident.</p></sec><sec><title>Conclusions</title><p>Association of <italic>ITGAV </italic>SNP <italic>rs7378919 </italic>with RA was not replicated in NZ or Oxford case control sample sets. Meta-analysis of these and previously published data lends limited support for a role for the <italic>ITGAV </italic>in RA in Caucasians of European ancestry.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>Rheumatoid arthritis (RA) is a common systemic autoimmune disease characterised by chronic synovial inflammation leading to the formation of invasive, destructive pannus. The extensive formation of new blood vessels within the affected joint (hyperangiogenesis) is an important component of pannus formation [<xref ref-type="bibr" rid="B1">1</xref>].</p><p>A heritable component to RA is supported by twin studies [<xref ref-type="bibr" rid="B2">2</xref>] and the markedly increased sibling recurrence risk (&#x003bb;<sub>s </sub>= 5 to 7.2) compared with the general population [<xref ref-type="bibr" rid="B3">3</xref>]. Association with the <italic>HLA-DRB1 </italic>locus is well established, with many other loci also incriminated. These include the protein tyrosine phosphatase non-receptor 22 (<italic>PTPN22</italic>) gene [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>], cytotoxic T-lymphocyte antigen 4 (<italic>CTLA4</italic>) [<xref ref-type="bibr" rid="B6">6</xref>], an intergenic region on human chromosome 6 [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>], signal transducer and activator of transcription 4 (<italic>STAT4</italic>) [<xref ref-type="bibr" rid="B9">9</xref>], the tumour necrosis factor receptor-associated factor 1 region (<italic>TRAF/C5</italic>) [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>] and CD40, CCL21 and IL2RB [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>].</p><p>The integrin &#x003b1;&#x003bd;&#x003b2;3 (<italic>ITGAV</italic>) locus contains 30 exons spanning more than 90 kb of genomic DNA on human chromosome 2q31. It encodes the &#x003b1;&#x003bd; subunit of the cell cycle-associated antigen, integrin &#x003b1;&#x003bd;&#x003b2;3, which plays a major role in RA angiogenesis. Angiogenesis is stimulated in RA by the increased metabolic demand of the pathologically active synovial tissues [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B16">16</xref>]. Potentially, inhibition of this angiogenesis might suppress the destructive activities of pannus and even control disease activity [<xref ref-type="bibr" rid="B17">17</xref>]. This is supported by studies in animal models in which injection of &#x003b1;&#x003bd;&#x003b2;3 antagonists has shown inhibition of neovascularisation and attenuation of joint inflammation [<xref ref-type="bibr" rid="B18">18</xref>].</p><p>A previous genome-wide linkage scan suggested 19 non-HLA regions contributing to RA in a French population [<xref ref-type="bibr" rid="B19">19</xref>]. One of these regions, on human chr2q31, contains the <italic>ITGAV </italic>gene (<italic>CD51</italic>). Subsequently, Jacq and colleagues [<xref ref-type="bibr" rid="B20">20</xref>] demonstrated an association between RA and the <italic>ITGAV rs3738919 </italic>C allele in a French Caucasian population (odds ratio for allele frequency difference [OR<sub><italic>allelic</italic></sub>] = 0.77, 95% confidence interval [CI] 0.63 to 0.94). Significant association with the <italic>rs3738919 </italic>C allele was also demonstrated from imputed data by the Wellcome Trust Case Control Consortium (WTCCC) (OR<sub><italic>allelic </italic></sub>= 0.91, 95% CI 0.83 to 1.00) [<xref ref-type="bibr" rid="B21">21</xref>]. Collectively, these studies suggest a role for <italic>ITGAV </italic>in RA and justify further investigation of this locus. We therefore tested this association in an independent study using New Zealand (NZ) and Oxford (UK) RA case control samples.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Study subjects</title><p>The NZ population-based Caucasian sample consists of 740 RA patients fulfilling the American College of Rheumatology (ACR) criteria for RA [<xref ref-type="bibr" rid="B22">22</xref>]. Of the patients for whom data were available, 34.3% (234/683) were male, 82.9% (538/649) were rheumatoid factor (RF)-positive, 68.1% (275/404) were anti-cyclic citrullinated peptide (anti-CCP)-positive and 79.4% (576/725) carried the <italic>HLA-DRB1 </italic>shared epitope. Ethical approval for recruitment of cases was given by the New Zealand Multi-Region Ethics Committee, and recruitment of the controls was approved by the Lower South Ethics Committee. All patients provided written informed consent for the collection of samples and subsequent analysis. The control sample consisted of 553 NZ European Caucasians (226/552 male; 40.9%) with no history of autoimmune disease.</p><p>The 713 UK patients were recruited in Oxford, with informed consent from attendees at the rheumatology outpatient clinic at the Nuffield Orthopaedic Centre. All fulfilled the 1987 ACR criteria for RA; the average age of onset was 48 years, 28% were male, 77% were positive for RF and 77% carried the <italic>HLA-DRB1 </italic>shared epitope. Healthy ethnically matched controls (n = 515) were recruited from the same locale as that of blood donors. Approval for the study was given by the Oxford Research Ethics Committee (OxRec number C02.032).</p></sec><sec><title>DNA extraction and genotyping</title><p>DNA was extracted from peripheral blood samples of the RA patients and controls by means of guanidine isothiocyanate-chloroform extraction methods. NZ study participants were genotyped for the <italic>ITGAV </italic>single-nucleotide polymorphism (SNP) <italic>rs3738919 </italic>using a polymerase chain reaction-restriction fragment length polymorphic SNP genotyping assay as follows: forward primer CACTTTCTGTAAATTAGTGTTAGATCAAAAGG and reverse primer GCTTATAACTCACAATTCAGATTTTTGCC (primers from Sigma-Genosys, Sydney, Australia). The C allele (major allele) of the <italic>rs3738919 </italic>product (286 base pairs) was digested using the <italic>Alu</italic>I restriction enzyme to form fragments of 223 and 63 base pairs. Oxford study participants were genotyped for <italic>rs3738919 </italic>using the TaqMan genotyping assay C___1278131_1, and both the NZ and Oxford samples were genotyped for the <italic>rs10174098 </italic>and <italic>rs3911238 ITGAV </italic>variants using the TaqMan genotyping assays C__30567648_10 and C___7617051_10, respectively, from Applied Biosystems (Scoresby, Australia).</p><p>Although the imputed <italic>rs3738919 </italic>data were available and were previously reported by Ahnert and Kirsten [<xref ref-type="bibr" rid="B21">21</xref>], we reimputed <italic>rs3738919 </italic>genotypes in order to provide information on imputation parameters. RA case and control genotypes were imputed from the WTCCC dataset using IMPUTE software [<xref ref-type="bibr" rid="B23">23</xref>]. Genotypes were imputed from 89% of cases (n = 1,659) and 90% of controls (n = 2,639) using a 7-Mb region and a calling threshold of 0.7.</p></sec><sec><title>Statistical analysis</title><p>An <italic>a priori </italic>power calculation was made based on the combined French [<xref ref-type="bibr" rid="B20">20</xref>] and WTCCC [<xref ref-type="bibr" rid="B21">21</xref>] OR (OR<sub><italic>allelic </italic></sub>= 1.16), using 800 cases and 600 controls with a major allele frequency of 65%. The power to detect association of <italic>rs3738919 </italic>to RA using either the NZ or Oxford sample set was estimated to be 47%, using &#x003b1; = 0.05. <italic>ITGAV </italic>SNPs were tested for deviation from Hardy-Weinberg equilibrium in both the control and RA samples using a chi-square goodness-of-fit test. The significance of differences in the minor allele frequency between RA patients and controls, and stratified patients, was assessed using the chi-square goodness-of-fit test.</p><p>Of the five <italic>ITGAV </italic>SNPs (<italic>rs3911238</italic>, <italic>rs2887827</italic>, <italic>rs10174098</italic>, <italic>rs13006571 </italic>and <italic>rs16828163</italic>) genotyped by the WTCCC and <italic>rs3738919</italic>, only three (<italic>rs3911238</italic>, <italic>rs10174098 </italic>and <italic>rs3738919</italic>) were required to tag all major haplotypes defined by the six variants. Haplotype association analysis was performed using the SHEsis software package [<xref ref-type="bibr" rid="B24">24</xref>], which uses a full-precise-iteration algorithm to construct haplotypes and estimate haplotype frequencies.</p><p>Meta-analysis combining the French [<xref ref-type="bibr" rid="B20">20</xref>], WTCCC [<xref ref-type="bibr" rid="B25">25</xref>], NZ and Oxford samples was performed using STATA version 8.0 (StataCorp LP, College Station, TX, USA). The Mantel-Haenszel test was used to estimate the average conditional common OR between the four independent sample sets and to test for any heterogeneity between the four groups using both fixed and random effects. R software [<xref ref-type="bibr" rid="B26">26</xref>] was used to perform the Cochran-Armitage trend test to determine recessive, additive and dominant trend values (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Allele and genotype distribution of <italic>rs3738919</italic></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Cohort</th><th align="center">Case, number (frequency)</th><th align="center">Control, number (frequency)</th><th align="center"><italic>P </italic>value</th><th align="center">OR (95% CI)</th></tr></thead><tbody><tr><td align="left">New Zealand</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Minor allele</td><td align="center">501 (0.339)</td><td align="center">408 (0.369)</td><td align="center">0.11</td><td align="center">0.88 (0.75-1.03)</td></tr><tr><td align="left">&#x02003;Genotype 1,1</td><td align="center">326 (0.38)</td><td align="center">210 (0.38)</td><td align="center">-</td><td align="center">1</td></tr><tr><td align="left">&#x02003;1,2</td><td align="center">327 (0.44)</td><td align="center">278 (0.50)</td><td align="center">0.021</td><td align="center">0.76 (0.60-0.96)</td></tr><tr><td align="left">&#x02003;2,2</td><td align="center">87 (0.12)</td><td align="center">65 (0.12)</td><td align="center">0.43</td><td align="center">0.86 (0.60-1.24)</td></tr><tr><td align="left">&#x02003;HWE</td><td align="center">0.72</td><td align="center">0.061</td><td/><td/></tr><tr><td align="left">&#x02003;Dominant</td><td/><td/><td align="center">0.028</td><td/></tr><tr><td align="left">&#x02003;Additive</td><td/><td/><td align="center">0.10</td><td/></tr><tr><td align="left">&#x02003;Recessive</td><td/><td/><td align="center">0.99</td><td/></tr><tr><td align="left">Oxford, UK</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Minor allele</td><td align="center">506 (0.355)</td><td align="center">329 (0.319)</td><td align="center">0.068</td><td align="center">1.17 (0.99-1.39)</td></tr><tr><td align="left">&#x02003;Genotype 1,1</td><td align="center">300 (0.42)</td><td align="center">235 (0.46)</td><td align="center">-</td><td align="center">1</td></tr><tr><td align="left">&#x02003;1,2</td><td align="center">319 (0.45)</td><td align="center">231 (0.45)</td><td align="center">0.52</td><td align="center">1.08 (0.85-1.38)</td></tr><tr><td align="left">&#x02003;2,2</td><td align="center">93 (0.13)</td><td align="center">49 (0.10)</td><td align="center">0.044</td><td align="center">1.49 (1.01-2.19)</td></tr><tr><td align="left">&#x02003;HWE</td><td align="center">0.60</td><td align="center">0.47</td><td/><td/></tr><tr><td align="left">&#x02003;Dominant</td><td/><td/><td align="center">0.22</td><td/></tr><tr><td align="left">&#x02003;Additive</td><td/><td/><td align="center">0.069</td><td/></tr><tr><td align="left">&#x02003;Recessive</td><td/><td/><td align="center">0.055</td><td/></tr><tr><td align="left">WTCCC</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Minor allele</td><td align="center">1,141 (0.344)</td><td align="center">1,928 (0.365)</td><td align="center">0.044</td><td align="center">0.91 (0.83-1.00)</td></tr><tr><td align="left">&#x02003;Genotype 1,1</td><td align="center">708 (0.43)</td><td align="center">1,044 (0.40)</td><td align="center">-</td><td align="center">1</td></tr><tr><td align="left">&#x02003;1,2</td><td align="center">761 (0.46)</td><td align="center">1,262 (0.48)</td><td align="center">0.079</td><td align="center">0.89 (0.78-1.01)</td></tr><tr><td align="left">&#x02003;2,2</td><td align="center">190 (0.11)</td><td align="center">333 (0.13)</td><td align="center">0.094</td><td align="center">0.84 (0.69-1.03)</td></tr><tr><td align="left">&#x02003;HWE</td><td align="center">0.50</td><td align="center">0.11</td><td/><td/></tr><tr><td align="left">&#x02003;Dominant</td><td/><td/><td align="center">0.043</td><td/></tr><tr><td align="left">&#x02003;Additive</td><td/><td/><td align="center">0.041</td><td/></tr><tr><td align="left">&#x02003;Recessive</td><td/><td/><td align="center">0.26</td><td/></tr><tr><td align="left">Jacq <italic>et al</italic>. [<xref ref-type="bibr" rid="B20">20</xref>]</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Minor allele</td><td align="center">292 (0.352)</td><td align="center">343 (0.413)</td><td align="center">0.01</td><td align="center">0.77 (0.63-0.94)</td></tr><tr><td align="left">&#x02003;Genotype 1,1</td><td align="center">166 (0.40)</td><td align="center">148 (0.36)</td><td align="center">-</td><td align="center">1</td></tr><tr><td align="left">&#x02003;1,2</td><td align="center">206 (0.50)</td><td align="center">191 (0.46)</td><td align="center">0.80</td><td align="center">0.96 (0.71-1.29)</td></tr><tr><td align="left">&#x02003;2,2</td><td align="center">43 (0.10)</td><td align="center">76 (0.18)</td><td align="center">0.002</td><td align="center">0.50 (0.33-0.78)</td></tr><tr><td align="left">&#x02003;HWE</td><td align="center">0.0718</td><td align="center">0.30</td><td/><td/></tr><tr><td align="left">&#x02003;Dominant</td><td/><td/><td align="center">0.20</td><td/></tr><tr><td align="left">&#x02003;Additive</td><td/><td/><td align="center">0.0096</td><td/></tr><tr><td align="left">&#x02003;Recessive</td><td/><td/><td align="center">0.0011</td><td/></tr><tr><td align="left">Combined</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Minor allele</td><td align="center">2,440 (0.346)</td><td align="center">3,008 (0.365)</td><td align="center">0.014</td><td align="center">0.92 (0.86-0.98)</td></tr><tr><td align="left">&#x02003;Genotype 1,1</td><td align="center">1,500 (0.43)</td><td align="center">1,637 (0.40)</td><td align="center">-</td><td align="center">1</td></tr><tr><td align="left">&#x02003;1,2</td><td align="center">1,614 (0.46)</td><td align="center">1,966 (0.48)</td><td align="center">0.028</td><td align="center">0.90 (0.81-0.99)</td></tr><tr><td align="left">&#x02003;2,2</td><td align="center">413 (0.12)</td><td align="center">523 (0.13)</td><td align="center">0.046</td><td align="center">0.86 (0.74-1.00)</td></tr><tr><td align="left">&#x02003;HWE</td><td align="center">0.51</td><td align="center">0.083</td><td/><td/></tr><tr><td align="left">&#x02003;Dominant</td><td/><td/><td align="center">0.011</td><td/></tr><tr><td align="left">&#x02003;Additive</td><td/><td/><td align="center">0.013</td><td/></tr><tr><td align="left">&#x02003;Recessive</td><td/><td/><td align="center">0.20</td><td/></tr></tbody></table><table-wrap-foot><p>CI, confidence interval; HWE, Hardy-Weinberg equilibrium <italic>P </italic>value; OR, odds ratio; WTCCC, Wellcome Trust Case Control Consortium.</p></table-wrap-foot></table-wrap></sec></sec><sec><title>Results</title><sec><title>Analysis of <italic>rs3738919 </italic>in New Zealand and Oxford Caucasian rheumatoid arthritis samples</title><p>We genotyped <italic>rs3738919 </italic>across the NZ and Oxford RA case control cohorts and found no evidence for an association between <italic>ITGAV </italic>and RA (<italic>P</italic><sub><italic>allelic </italic></sub>= 0.11; OR<sub><italic>allelic </italic></sub>= 0.88 [95% CI 0.75 to 1.03] and <italic>P</italic><sub><italic>allelic </italic></sub>= 0.07; OR<sub><italic>allelic </italic></sub>= 1.17 [95% CI 0.99 to 1.39], respectively) (Table <xref ref-type="table" rid="T1">1</xref>). The direction of the NZ allele distribution is consistent with the previous French [<xref ref-type="bibr" rid="B20">20</xref>] and WTCCC [<xref ref-type="bibr" rid="B21">21</xref>] data, with the minor allele under-represented in the case groups in all three cohorts (Table <xref ref-type="table" rid="T1">1</xref>). However, the allele distribution in the Oxford RA cohort differs in that the minor allele is over-represented in the patient group compared with the control group (Table <xref ref-type="table" rid="T1">1</xref>).</p></sec><sec><title>Haplotype analysis</title><p>Association analysis using our imputed genotypes for <italic>rs3738919 </italic>(<italic>P </italic>= 0.04) from the WTCCC data were consistent with the previous report of an association of this SNP with RA in the WTCCC [<xref ref-type="bibr" rid="B21">21</xref>]. In our analysis, we obtained imputed genotypes from 89% of the WTCCC case control subjects. Presumably, this reflects the influence of the low linkage disequilibrium that exists between <italic>rs3738919 </italic>and the genotyped SNPs (0.01 &#x0003c;<italic>r</italic><sup>2 </sup>&#x0003c; 0.54 in CEU [Centre d'Etude du Polymorphisme Humain Utah] HapMap [<xref ref-type="bibr" rid="B27">27</xref>]) on confidence calls of imputed genotypes. Haplotype analysis (Table <xref ref-type="table" rid="T2">2</xref>) was performed using the actual genotypes from <italic>ITGAV </italic>SNPs <italic>rs3911238 </italic>and <italic>rs10174098 </italic>(Additional data file <xref ref-type="supplementary-material" rid="S1">1</xref>) and the imputed genotypes for <italic>rs3738919 </italic>(Table <xref ref-type="table" rid="T1">1</xref>). One susceptibility haplotype (1-1-1), containing the major allele at each of the three SNPs, was significantly over-represented in cases compared with controls (OR = 1.15, 95% CI 1.02 to 1.30; <italic>P </italic>= 0.021).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Three-marker haplotype analysis of <italic>ITGAV </italic>single-nucleotide polymorphisms (<italic>rs10174098</italic>, <italic>rs3911238</italic>, <italic>rs3738919</italic>) in the Wellcome Trust Case Control Consortium, New Zealand and Oxford sample sets</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><italic>rs10174098</italic></th><th align="center"><italic>rs3911238</italic></th><th align="center"><italic>rs3738919</italic></th><th align="center">Case, number (frequency)</th><th align="center">Control, number (frequency)</th><th align="center"><italic>P </italic>value</th><th align="center">OR (95% CI)</th></tr></thead><tbody><tr><td align="left">WTCCC</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;1</td><td align="center">1</td><td align="center">2</td><td align="center">866 (0.261)</td><td align="center">1,451 (0.275)</td><td align="center">0.19</td><td align="center">0.94 (0.85-1.03)</td></tr><tr><td align="left">&#x02003;2</td><td align="center">1</td><td align="center">1</td><td align="center">858 (0.259)</td><td align="center">1,382 (0.262)</td><td align="center">0.82</td><td align="center">0.99 (0.90-1.09)</td></tr><tr><td align="left">&#x02003;1</td><td align="center">2</td><td align="center">1</td><td align="center">792 (0.239)</td><td align="center">1,226 (0.232)</td><td align="center">0.43</td><td align="center">1.04 (0.94-1.16)</td></tr><tr><td align="left">&#x02003;1</td><td align="center">1</td><td align="center">1</td><td align="center">524 (0.158)</td><td align="center">741 (0.140)</td><td align="center">0.021</td><td align="center">1.15 (1.02-1.30)</td></tr><tr><td align="left">&#x02003;2</td><td align="center">1</td><td align="center">2</td><td align="center">219 (0.066)</td><td align="center">405 (0.077)</td><td align="center">0.070</td><td align="center">0.85 (0.72-1.01)</td></tr><tr><td align="left">New Zealand</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;1</td><td align="center">1</td><td align="center">2</td><td align="center">357 (0.244)</td><td align="center">260 (0.263)</td><td align="center">0.29</td><td align="center">0.90 (0.75~1.09)</td></tr><tr><td align="left">&#x02003;2</td><td align="center">1</td><td align="center">1</td><td align="center">364 (0.249)</td><td align="center">240 (0.243)</td><td align="center">0.73</td><td align="center">1.03 (0.86~1.25)</td></tr><tr><td align="left">&#x02003;1</td><td align="center">2</td><td align="center">1</td><td align="center">359 (0.246)</td><td align="center">223 (0.225)</td><td align="center">0.26</td><td align="center">1.12 (0.92~1.35)</td></tr><tr><td align="left">&#x02003;1</td><td align="center">1</td><td align="center">1</td><td align="center">241 (0.165)</td><td align="center">170 (0.172)</td><td align="center">0.60</td><td align="center">0.95 (0.76~1.17)</td></tr><tr><td align="left">&#x02003;2</td><td align="center">1</td><td align="center">2</td><td align="center">110 (0.075)</td><td align="center">73 (0.074)</td><td align="center">0.91</td><td align="center">1.02 (0.75~1.39)</td></tr><tr><td align="left">Oxford, UK</td><td/><td/><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;1</td><td align="center">1</td><td align="center">2</td><td align="center">310 (0.256)</td><td align="center">252 (0.253)</td><td align="center">0.80</td><td align="center">1.03 (0.85-1.24)</td></tr><tr><td align="left">&#x02003;2</td><td align="center">1</td><td align="center">1</td><td align="center">306 (0.253)</td><td align="center">262 (0.262)</td><td align="center">0.67</td><td align="center">0.96 (0.79-1.16)</td></tr><tr><td align="left">&#x02003;1</td><td align="center">2</td><td align="center">1</td><td align="center">335 (0.277)</td><td align="center">251 (0.252)</td><td align="center">0.16</td><td align="center">1.15 (0.95-1.39)</td></tr><tr><td align="left">&#x02003;1</td><td align="center">1</td><td align="center">1</td><td align="center">158 (0.130)</td><td align="center">162 (0.162)</td><td align="center">0.04</td><td align="center">0.78 (0.62-0.99)</td></tr><tr><td align="left">&#x02003;2</td><td align="center">1</td><td align="center">2</td><td align="center">78 (0.064)</td><td align="center">57 (0.057)</td><td align="center">0.47</td><td align="center">1.14 (0.80-1.62)</td></tr></tbody></table><table-wrap-foot><p>Only haplotypes with frequency of at least 0.05 in controls are shown. CI, confidence interval; HWE, Hardy-Weinberg equilibrium; OR, odds ratio; WTCCC, Wellcome Trust Case Control Consortium.</p></table-wrap-foot></table-wrap><p>Variants <italic>rs3911238 </italic>and <italic>rs10174098 </italic>were typed over the NZ and Oxford sample sets, and association of three-marker haplotypes was examined (Additional data file <xref ref-type="supplementary-material" rid="S1">1</xref> and Table <xref ref-type="table" rid="T2">2</xref>). There was no support for a positive association of the 1-1-1 haplotype with RA in either the NZ or Oxford sample set. There was a significant protective effect for this haplotype in the Oxford samples (OR = 0.78, 95% CI 0.62 to 0.99; <italic>P </italic>= 0.042).</p></sec><sec><title>Meta-analysis of <italic>ITGAV </italic>in the four independent case control sample sets</title><p>Meta-analysis of all four sample sets, using a fixed effects model, revealed some evidence for an association of <italic>rs3738919 </italic>with RA (OR = 0.92, 95% CI 0.86 to 0.99; <italic>P </italic>= 0.021) (Figure <xref ref-type="fig" rid="F1">1a</xref>). Because of evidence for heterogeneity between the sample sets (Breslow-Day <italic>P </italic>= 0.011), a random effects model was also used for meta-analysis; this did not provide evidence for an association of <italic>rs3738919 </italic>with RA (OR = 0.92, 95% CI 0.80 to 1.07; <italic>P </italic>= 0.29) (Figure <xref ref-type="fig" rid="F1">1b</xref>). The Oxford sample set is significantly different from the other three sample sets at <italic>rs3738919</italic>; however, the Oxford patient sample set did not have any large differences in relation to gender (Oxford 28% male, NZ 34%, WTCCC 25%, France 13%), RF status (Oxford 77% positive, NZ 83%, WTCCC 84%, France 75%) or inheritance of the shared epitope (Oxford 77% positive, NZ 79%, WTCCC 79%, France 79%).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Meta-analysis of the <italic>ITGAV </italic>single-nucleotide polymorphism <italic>rs3738919 </italic>in four independent rheumatoid arthritis Caucasian cohorts: Jacq and colleagues [<xref ref-type="bibr" rid="B20">20</xref>], Wellcome Trust Case Control Consortium (WTCCC) [<xref ref-type="bibr" rid="B25">25</xref>], New Zealand and Oxford sample sets. <bold>(a) </bold>Fixed effects model. <bold>(b) </bold>Random effects model. CI, confidence interval.</p></caption><graphic xlink:href="ar2828-1"/></fig></sec><sec><title>Stratification according to subphenotype</title><p>The NZ and Oxford samples were stratified according to gender, RF and shared epitope status (Table <xref ref-type="table" rid="T3">3</xref>). The stratification results did not reveal any significant differences in the <italic>rs3738919 </italic>genotype distribution for RA patients. There was a difference in the <italic>rs3738919 </italic>genotype distribution of male and female patients in the NZ cases (<italic>P </italic>= 0.026) (Table <xref ref-type="table" rid="T3">3</xref>). However, a significant difference was not evident in either the Oxford or WTCCC case sample set (<italic>P </italic>= 0.55 and 0.80, respectively) (Table <xref ref-type="table" rid="T3">3</xref>).</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Subphenotype analysis of <italic>rs3738919 </italic>in rheumatoid arthritis patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center">CC, number (frequency)</th><th align="center">CA, number (frequency)</th><th align="center">AA, number (frequency)</th><th align="center"><italic>P </italic>value</th></tr></thead><tbody><tr><td align="left">New Zealand</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Gender</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;&#x02003;Male</td><td align="center">117 (0.500)</td><td align="center">90 (0.385)</td><td align="center">27 (0.115)</td><td align="center">0.026</td></tr><tr><td align="left">&#x02003;&#x02003;Female</td><td align="center">177 (0.394)</td><td align="center">216 (0.481)</td><td align="center">56 (0.125)</td><td/></tr><tr><td align="left">&#x02003;RF</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;&#x02003;Yes</td><td align="center">232 (0.431)</td><td align="center">239 (0.444)</td><td align="center">67 (0.125)</td><td align="center">0.75</td></tr><tr><td align="left">&#x02003;&#x02003;No</td><td align="center">49 (0.441)</td><td align="center">51 (0.459)</td><td align="center">11 (0.100)</td><td/></tr><tr><td align="left">&#x02003;SE</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;&#x02003;Yes</td><td align="center">241 (0.418)</td><td align="center">269 (0.467)</td><td align="center">66 (0.115)</td><td align="center">0.05</td></tr><tr><td align="left">&#x02003;&#x02003;No</td><td align="center">75 (0.503)</td><td align="center">53 (0.356)</td><td align="center">21 (0.141)</td><td/></tr><tr><td align="left">Oxford, UK</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Gender</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;&#x02003;Male</td><td align="center">89 (0.434)</td><td align="center">86 (0.420)</td><td align="center">30 (0.146)</td><td align="center">0.55</td></tr><tr><td align="left">&#x02003;&#x02003;Female</td><td align="center">211 (0.416)</td><td align="center">233 (0.460)</td><td align="center">63 (0.124)</td><td/></tr><tr><td align="left">&#x02003;RF</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;&#x02003;Yes</td><td align="center">227 (0.411)</td><td align="center">247 (0.447)</td><td align="center">78 (0.141)</td><td align="center">0.34</td></tr><tr><td align="left">&#x02003;&#x02003;No</td><td align="center">69 (0.454)</td><td align="center">68 (0.447)</td><td align="center">15 (0.099)</td><td/></tr><tr><td align="left">&#x02003;SE</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;&#x02003;Yes</td><td align="center">226 (0.410)</td><td align="center">254 (0.461)</td><td align="center">71 (0.129)</td><td align="center">0.47</td></tr><tr><td align="left">&#x02003;&#x02003;No</td><td align="center">74 (0.457)</td><td align="center">66 (0.407)</td><td align="center">22 (0.136)</td><td/></tr><tr><td align="left">WTCCC</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;Gender</td><td/><td/><td/><td/></tr><tr><td align="left">&#x02003;&#x02003;Male</td><td align="center">180 (0.438)</td><td align="center">187 (0.455)</td><td align="center">44 (0.107)</td><td align="center">0.80</td></tr><tr><td align="left">&#x02003;&#x02003;Female</td><td align="center">528 (0.423)</td><td align="center">574 (0.460)</td><td align="center">146 (0.117)</td><td/></tr></tbody></table><table-wrap-foot><p>RF, rheumatoid factor; SE, shared epitope; WTCCC, Wellcome Trust Case Control Consortium.</p></table-wrap-foot></table-wrap></sec></sec><sec><title>Discussion</title><p>There was no evidence supporting a role for the <italic>ITGAV </italic>SNP <italic>rs3738919 </italic>in the etiology of RA when the NZ and the Oxford case control sample sets were analysed separately (<italic>P </italic>= 0.11 and 0.07, respectively) (Table <xref ref-type="table" rid="T1">1</xref>). Trends for association were observed in both sets of samples, but in opposing directions (OR = 0.86 and 1.18, respectively). When all of the available sample sets were analysed together in a random effects model owing to the heterogeneity caused by the Oxford sample set, there was no longer evidence for an association of <italic>rs3738919 </italic>with RA (OR = 0.92; <italic>P </italic>= 0.29). To further investigate a potential association of RA with <italic>rs3738919</italic>, genotyping in a very large cohort will be required. The work previously undertaken by Thomson and colleagues [<xref ref-type="bibr" rid="B8">8</xref>] in confirming an association with RA of the Chr6q23 locus is an excellent example of how this can be achieved. A sample set of this size would have 69% power (&#x003b1; = 0.05; OR = 0.92) to detect association at <italic>rs3738919</italic>.</p><p>The rs3738919 <italic>ITGAV </italic>variant previously showed no association with RA in Japanese case-control samples [<xref ref-type="bibr" rid="B28">28</xref>]. These data were not included in our meta-analysis given that the major allele was present at a considerably different frequency in Japanese controls (0.92) than in Caucasian controls (France, 0.58; OXFORD, 0.64; and NZ, 0.63). It is already clear that there are genetic differences in susceptibility to RA between the Japanese and Caucasian populations. For example, the <italic>HLA-DRB1*0405 </italic>allele is most strongly associated with RA in Japanese patients [<xref ref-type="bibr" rid="B29">29</xref>] whereas the <italic>*0401 </italic>and <italic>*0404 </italic>alleles are more associated with RA in Caucasians [<xref ref-type="bibr" rid="B30">30</xref>]. Other genes showing population-specific effects in RA are the R620W variant of the protein tyrosine phosphatase, <italic>PTPN22</italic>, associated with Caucasian RA [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>] but monomorphic in the Japanese population [<xref ref-type="bibr" rid="B31">31</xref>]; <italic>CTLA4</italic>, associated with RA in Caucasian [<xref ref-type="bibr" rid="B6">6</xref>] but not associated with RA in Japanese patients [<xref ref-type="bibr" rid="B32">32</xref>]; peptidylarginine deiminase type 4, <italic>PADI4</italic>, associated in Japanese patients [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B34">34</xref>] but very weakly in Caucasians [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref>]; and the Fc receptor-like 3 gene variant, <italic>FCRL3-169C</italic>, associated with RA in Japanese patients [<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B38">38</xref>] and in one Caucasian study [<xref ref-type="bibr" rid="B39">39</xref>] but not in other Caucasian studies [<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B41">41</xref>]. In conclusion, we have not been able to provide further support for the involvement of <italic>ITGAV </italic>in the etiology of RA in Caucasians. However, it is important that further genotyping be done in a large independent cohort to confirm whether <italic>ITGAV </italic>plays a role in RA.</p></sec><sec><title>Conclusions</title><p>In Caucasians, meta-analysis of 3,527 cases and 4,126 controls does not provide further evidence for a role of the <italic>ITGAV </italic>SNP <italic>rs3738919 </italic>in the development of RA.</p></sec><sec><title>Abbreviations</title><p>ACR: American College of Rheumatology; CI: confidence interval; CTLA4: cytotoxic T-lymphocyte antigen 4; ITGAV: integrin &#x003b1;&#x003bd;&#x003b2;3; NZ: New Zealand; OR: odds ratio; OR<sub><italic>allelic</italic></sub>: odds ratio for allele frequency difference; PTPN22: protein tyrosine phosphatase non-receptor 22; RA: rheumatoid arthritis; RF: rheumatoid factor; SNP: single-nucleotide polymorphism; WTCCC: Wellcome Trust Case Control Consortium.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>JEH-M and TRM helped to design the study, oversee its execution, and prepare the manuscript. KAR, AJP-G and MEM provided technical support. PG, AAH, PBBJ, LKS and PH helped to provide clinical recruitment and analyse data. ND, JH and BPW helped to provide clinical recruitment, analyse data, and prepare the manuscript. All authors read and approved the final manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p>Allele and genotype distribution of <italic>rs10174098 </italic>and <italic>rs3911238</italic>. OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium; UK, United Kingdom; WTCCC, Wellcome Trust Case Control Consortium.</p></caption><media xlink:href="ar2828-S1.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><p>We thank all of the people who agreed to participate in our study and the Wellcome Trust Case Control Consortium for access to genotype data; Rachel Rodger, Helen Simkins, Wan Rohani Wan Taib and Cushla McKinney for assistance with laboratory work and data analysis; New Zealand research nurses Gael Hewett and Jill James for assistance in recruiting patients; and the Health Research Council of New Zealand and Arthritis New Zealand for their financial support of this work. This work was funded in part by a departmental grant from the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Paleolog</surname><given-names>EM</given-names></name><article-title>Angiogenesis in rheumatoid arthritis</article-title><source>Arthritis Res</source><year>2002</year><volume>4</volume><fpage>S81</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1186/ar575</pub-id><pub-id pub-id-type="pmid">12110126</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Silman</surname><given-names>AJ</given-names></name><name><surname>MacGregor</surname><given-names>AJ</given-names></name><name><surname>Thomson</surname><given-names>W</given-names></name><name><surname>Holligan</surname><given-names>S</given-names></name><name><surname>Carthy</surname><given-names>D</given-names></name><name><surname>Farhan</surname><given-names>A</given-names></name><name><surname>Ollier</surname><given-names>WE</given-names></name><article-title>Twin concordance rates for rheumatoid arthritis: results from a nationwide study</article-title><source>Br J Rheumatol</source><year>1993</year><volume>32</volume><fpage>903</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/32.10.903</pub-id><pub-id pub-id-type="pmid">8402000</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Wordsworth</surname><given-names>P</given-names></name><name><surname>Bell</surname><given-names>J</given-names></name><article-title>Polygenic susceptibility in rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><year>1991</year><volume>50</volume><fpage>343</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1136/ard.50.6.343</pub-id><pub-id pub-id-type="pmid">2059076</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Begovich</surname><given-names>AB</given-names></name><name><surname>Carlton</surname><given-names>VE</given-names></name><name><surname>Honigberg</surname><given-names>LA</given-names></name><name><surname>Schrodi</surname><given-names>SJ</given-names></name><name><surname>Chokkalingam</surname><given-names>AP</given-names></name><name><surname>Alexander</surname><given-names>HC</given-names></name><name><surname>Ardlie</surname><given-names>KG</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Smith</surname><given-names>AM</given-names></name><name><surname>Spoerke</surname><given-names>JM</given-names></name><name><surname>Conn</surname><given-names>MY</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>SY</given-names></name><name><surname>Saiki</surname><given-names>RK</given-names></name><name><surname>Catanese</surname><given-names>JJ</given-names></name><name><surname>Leong</surname><given-names>DU</given-names></name><name><surname>Garcia</surname><given-names>VE</given-names></name><name><surname>McAllister</surname><given-names>LB</given-names></name><name><surname>Jeffery</surname><given-names>DA</given-names></name><name><surname>Lee</surname><given-names>AT</given-names></name><name><surname>Batliwalla</surname><given-names>F</given-names></name><name><surname>Remmers</surname><given-names>E</given-names></name><name><surname>Criswell</surname><given-names>LA</given-names></name><name><surname>Seldin</surname><given-names>MF</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Sninsky</surname><given-names>JJ</given-names></name><name><surname>Gregersen</surname><given-names>PK</given-names></name><article-title>A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis</article-title><source>Am J Hum Genet</source><year>2004</year><volume>75</volume><fpage>330</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1086/422827</pub-id><pub-id pub-id-type="pmid">15208781</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Simkins</surname><given-names>HM</given-names></name><name><surname>Merriman</surname><given-names>ME</given-names></name><name><surname>Highton</surname><given-names>J</given-names></name><name><surname>Chapman</surname><given-names>PT</given-names></name><name><surname>O'Donnell</surname><given-names>JL</given-names></name><name><surname>Jones</surname><given-names>PB</given-names></name><name><surname>Gow</surname><given-names>PJ</given-names></name><name><surname>McLean</surname><given-names>L</given-names></name><name><surname>Pokorny</surname><given-names>V</given-names></name><name><surname>Harrison</surname><given-names>AA</given-names></name><name><surname>Merriman</surname><given-names>TR</given-names></name><article-title>Association of the PTPN22 locus with rheumatoid arthritis in a New Zealand Caucasian cohort</article-title><source>Arthritis Rheum</source><year>2005</year><volume>52</volume><fpage>2222</fpage><lpage>2225</lpage><pub-id pub-id-type="doi">10.1002/art.21126</pub-id><pub-id pub-id-type="pmid">15986352</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Plenge</surname><given-names>RM</given-names></name><name><surname>Padyukov</surname><given-names>L</given-names></name><name><surname>Remmers</surname><given-names>EF</given-names></name><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>AT</given-names></name><name><surname>Karlson</surname><given-names>EW</given-names></name><name><surname>Wolfe</surname><given-names>F</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Alfredsson</surname><given-names>L</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Gregersen</surname><given-names>PK</given-names></name><name><surname>Klareskog</surname><given-names>L</given-names></name><name><surname>Rioux</surname><given-names>JD</given-names></name><article-title>Replication of putative candidate-gene associations with rheumatoid arthritis in &#x0003e;4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4</article-title><source>Am J Hum Genet</source><year>2005</year><volume>77</volume><fpage>1044</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1086/498651</pub-id><pub-id pub-id-type="pmid">16380915</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Plenge</surname><given-names>RM</given-names></name><name><surname>Seielstad</surname><given-names>M</given-names></name><name><surname>Padyukov</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>AT</given-names></name><name><surname>Remmers</surname><given-names>EF</given-names></name><name><surname>Ding</surname><given-names>B</given-names></name><name><surname>Liew</surname><given-names>A</given-names></name><name><surname>Khalili</surname><given-names>H</given-names></name><name><surname>Chandrasekaran</surname><given-names>A</given-names></name><name><surname>Davies</surname><given-names>LR</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>AK</given-names></name><name><surname>Bonnard</surname><given-names>C</given-names></name><name><surname>Ong</surname><given-names>RT</given-names></name><name><surname>Thalamuthu</surname><given-names>A</given-names></name><name><surname>Pettersson</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Tian</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>WV</given-names></name><name><surname>Carulli</surname><given-names>JP</given-names></name><name><surname>Beckman</surname><given-names>EM</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Alfredsson</surname><given-names>L</given-names></name><name><surname>Criswell</surname><given-names>LA</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Seldin</surname><given-names>MF</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Klareskog</surname><given-names>L</given-names></name><name><surname>Gregersen</surname><given-names>PK</given-names></name><article-title>TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>1199</fpage><lpage>1209</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa073491</pub-id><pub-id pub-id-type="pmid">17804836</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Thomson</surname><given-names>W</given-names></name><name><surname>Barton</surname><given-names>A</given-names></name><name><surname>Ke</surname><given-names>X</given-names></name><name><surname>Eyre</surname><given-names>S</given-names></name><name><surname>Hinks</surname><given-names>A</given-names></name><name><surname>Bowes</surname><given-names>J</given-names></name><name><surname>Donn</surname><given-names>R</given-names></name><name><surname>Symmons</surname><given-names>D</given-names></name><name><surname>Hider</surname><given-names>S</given-names></name><name><surname>Bruce</surname><given-names>IN</given-names></name><name><surname>Wilson</surname><given-names>AG</given-names></name><name><surname>Marinou</surname><given-names>I</given-names></name><name><surname>Morgan</surname><given-names>A</given-names></name><name><surname>Emery</surname><given-names>P</given-names></name><name><surname>Carter</surname><given-names>A</given-names></name><name><surname>Steer</surname><given-names>S</given-names></name><name><surname>Hocking</surname><given-names>L</given-names></name><name><surname>Reid</surname><given-names>DM</given-names></name><name><surname>Wordsworth</surname><given-names>P</given-names></name><name><surname>Harrison</surname><given-names>P</given-names></name><name><surname>Strachan</surname><given-names>D</given-names></name><name><surname>Worthington</surname><given-names>J</given-names></name><article-title>Rheumatoid arthritis association at 6q23</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>1431</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1038/ng.2007.32</pub-id><pub-id pub-id-type="pmid">17982455</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Remmers</surname><given-names>EF</given-names></name><name><surname>Plenge</surname><given-names>RM</given-names></name><name><surname>Lee</surname><given-names>AT</given-names></name><name><surname>Graham</surname><given-names>RR</given-names></name><name><surname>Hom</surname><given-names>G</given-names></name><name><surname>Behrens</surname><given-names>TW</given-names></name><name><surname>de Bakker</surname><given-names>PI</given-names></name><name><surname>Le</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Batliwalla</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Masters</surname><given-names>SL</given-names></name><name><surname>Booty</surname><given-names>MG</given-names></name><name><surname>JP</surname><given-names>Carulli</given-names></name><name><surname>Padyukov</surname><given-names>L</given-names></name><name><surname>Alfredsson</surname><given-names>L</given-names></name><name><surname>Klareskog</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>WV</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Criswell</surname><given-names>LA</given-names></name><name><surname>Seldin</surname><given-names>MF</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Gregersen</surname><given-names>PK</given-names></name><article-title>STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>977</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa073003</pub-id><pub-id pub-id-type="pmid">17804842</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Barton</surname><given-names>A</given-names></name><name><surname>Thomson</surname><given-names>W</given-names></name><name><surname>Ke</surname><given-names>X</given-names></name><name><surname>Eyre</surname><given-names>S</given-names></name><name><surname>Hinks</surname><given-names>A</given-names></name><name><surname>Bowes</surname><given-names>J</given-names></name><name><surname>Gibbons</surname><given-names>L</given-names></name><name><surname>Plant</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>AG</given-names></name><name><surname>Marinou</surname><given-names>I</given-names></name><name><surname>Morgan</surname><given-names>A</given-names></name><name><surname>Emery</surname><given-names>P</given-names></name><name><surname>Steer</surname><given-names>S</given-names></name><name><surname>Hocking</surname><given-names>L</given-names></name><name><surname>Reid</surname><given-names>DM</given-names></name><name><surname>Wordsworth</surname><given-names>P</given-names></name><name><surname>Harrison</surname><given-names>P</given-names></name><name><surname>Worthington</surname><given-names>J</given-names></name><article-title>Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility</article-title><source>Hum Mol Genet</source><year>2008</year><volume>17</volume><fpage>2274</fpage><lpage>2279</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddn128</pub-id><pub-id pub-id-type="pmid">18434327</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Rowland</surname><given-names>CM</given-names></name><name><surname>Garcia</surname><given-names>VE</given-names></name><name><surname>Schrodi</surname><given-names>SJ</given-names></name><name><surname>Catanese</surname><given-names>JJ</given-names></name><name><surname>Helm-van Mil</surname><given-names>AH van der</given-names></name><name><surname>Ardlie</surname><given-names>KG</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Criswell</surname><given-names>LA</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Gregersen</surname><given-names>PK</given-names></name><name><surname>Kurreeman</surname><given-names>FA</given-names></name><name><surname>Toes</surname><given-names>RE</given-names></name><name><surname>Huizinga</surname><given-names>TW</given-names></name><name><surname>Seldin</surname><given-names>MF</given-names></name><name><surname>Begovich</surname><given-names>AB</given-names></name><article-title>A large-scale rheumatoid arthritis genetic study identifies association at chromosome 9q33.2</article-title><source>PLoS Genet</source><year>2008</year><volume>4</volume><fpage>e1000107</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1000107</pub-id><pub-id pub-id-type="pmid">18648537</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Raychaudhuri</surname><given-names>S</given-names></name><name><surname>Remmers</surname><given-names>EF</given-names></name><name><surname>Lee</surname><given-names>AT</given-names></name><name><surname>Hackett</surname><given-names>R</given-names></name><name><surname>Guiducci</surname><given-names>C</given-names></name><name><surname>Burtt</surname><given-names>NP</given-names></name><name><surname>Gianniny</surname><given-names>L</given-names></name><name><surname>Korman</surname><given-names>BD</given-names></name><name><surname>Padyukov</surname><given-names>L</given-names></name><name><surname>Kurreeman</surname><given-names>FA</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Catanese</surname><given-names>JJ</given-names></name><name><surname>Ding</surname><given-names>B</given-names></name><name><surname>Wong</surname><given-names>S</given-names></name><name><surname>Helm-van Mil</surname><given-names>AH van der</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Coblyn</surname><given-names>J</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><name><surname>Wolbink</surname><given-names>GJ</given-names></name><name><surname>Crusius</surname><given-names>JB</given-names></name><name><surname>Horst-Bruinsma</surname><given-names>IE van der</given-names></name><name><surname>Criswell</surname><given-names>LA</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Seldin</surname><given-names>MF</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Ardlie</surname><given-names>KG</given-names></name><name><surname>Alfredsson</surname><given-names>L</given-names></name><name><surname>Costenbader</surname><given-names>KH</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><article-title>Common variants at CD40 and other loci confer risk of rheumatoid arthritis</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>1216</fpage><lpage>1223</lpage><pub-id pub-id-type="doi">10.1038/ng.233</pub-id><pub-id pub-id-type="pmid">18794853</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Barton</surname><given-names>A</given-names></name><name><surname>Thomson</surname><given-names>W</given-names></name><name><surname>Ke</surname><given-names>X</given-names></name><name><surname>Eyre</surname><given-names>S</given-names></name><name><surname>Hinks</surname><given-names>A</given-names></name><name><surname>Bowes</surname><given-names>J</given-names></name><name><surname>Plant</surname><given-names>D</given-names></name><name><surname>Gibbons</surname><given-names>LJ</given-names></name><collab>Wellcome Trust Case Control Consortium </collab><collab>YEAR Consortium</collab><collab>BIRAC Consortium</collab><name><surname>Wilson</surname><given-names>AG</given-names></name><name><surname>Bax</surname><given-names>DE</given-names></name><name><surname>Morgan</surname><given-names>AW</given-names></name><name><surname>Emery</surname><given-names>P</given-names></name><name><surname>Steer</surname><given-names>S</given-names></name><name><surname>Hocking</surname><given-names>L</given-names></name><name><surname>Reid</surname><given-names>DM</given-names></name><name><surname>Wordsworth</surname><given-names>P</given-names></name><name><surname>Harrison</surname><given-names>P</given-names></name><name><surname>Worthington</surname><given-names>J</given-names></name><article-title>Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>1156</fpage><lpage>1159</lpage><pub-id pub-id-type="pmid">18794857</pub-id><pub-id pub-id-type="doi">10.1038/ng.218</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Kimball</surname><given-names>ES</given-names></name><name><surname>Gross</surname><given-names>JL</given-names></name><article-title>Angiogenesis in pannus formation</article-title><source>Agents Actions</source><year>1991</year><volume>34</volume><fpage>329</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1007/BF01988724</pub-id><pub-id pub-id-type="pmid">1725688</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Stupack</surname><given-names>DG</given-names></name><name><surname>Storgard</surname><given-names>CM</given-names></name><name><surname>Cheresh</surname><given-names>DA</given-names></name><article-title>A role for angiogenesis in rheumatoid arthritis</article-title><source>Braz J Med Biol Res</source><year>1999</year><volume>32</volume><fpage>573</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1590/S0100-879X1999000500011</pub-id><pub-id pub-id-type="pmid">10412569</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Clavel</surname><given-names>G</given-names></name><name><surname>Bessis</surname><given-names>N</given-names></name><name><surname>Boissier</surname><given-names>MC</given-names></name><article-title>Recent data on the role for angiogenesis in rheumatoid arthritis</article-title><source>Joint Bone Spine</source><year>2003</year><volume>70</volume><fpage>321</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1016/S1297-319X(03)00088-5</pub-id><pub-id pub-id-type="pmid">14563458</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Pandya</surname><given-names>NM</given-names></name><name><surname>Dhalla</surname><given-names>NS</given-names></name><name><surname>Santani</surname><given-names>DD</given-names></name><article-title>Angiogenesis--a new target for future therapy</article-title><source>Vascul Pharmacol</source><year>2006</year><volume>44</volume><fpage>265</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1016/j.vph.2006.01.005</pub-id><pub-id pub-id-type="pmid">16545987</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Storgard</surname><given-names>CM</given-names></name><name><surname>Stupack</surname><given-names>DG</given-names></name><name><surname>Jonczyk</surname><given-names>A</given-names></name><name><surname>Goodman</surname><given-names>SL</given-names></name><name><surname>Fox</surname><given-names>RI</given-names></name><name><surname>Cheresh</surname><given-names>DA</given-names></name><article-title>Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist</article-title><source>J Clin Invest</source><year>1999</year><volume>103</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1172/JCI3756</pub-id><pub-id pub-id-type="pmid">9884333</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Osorio-Fortea</surname><given-names>YJ</given-names></name><name><surname>Bukulmez</surname><given-names>H</given-names></name><name><surname>Petit-Teixeira</surname><given-names>E</given-names></name><name><surname>Michou</surname><given-names>L</given-names></name><name><surname>Pierlot</surname><given-names>C</given-names></name><name><surname>Cailleau-Moindrault</surname><given-names>S</given-names></name><name><surname>Lemaire</surname><given-names>I</given-names></name><name><surname>Lasbleiz</surname><given-names>S</given-names></name><name><surname>Alibert</surname><given-names>O</given-names></name><name><surname>Quillet</surname><given-names>P</given-names></name><name><surname>Bardin</surname><given-names>T</given-names></name><name><surname>Prum</surname><given-names>B</given-names></name><name><surname>Olson</surname><given-names>JM</given-names></name><name><surname>Cornelis</surname><given-names>F</given-names></name><article-title>Dense genome-wide linkage analysis of rheumatoid arthritis, including covariates</article-title><source>Arthritis Rheum</source><year>2004</year><volume>50</volume><fpage>2757</fpage><lpage>2765</lpage><pub-id pub-id-type="doi">10.1002/art.20458</pub-id><pub-id pub-id-type="pmid">15457443</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Jacq</surname><given-names>L</given-names></name><name><surname>Garnier</surname><given-names>S</given-names></name><name><surname>Dieude</surname><given-names>P</given-names></name><name><surname>Michou</surname><given-names>L</given-names></name><name><surname>Pierlot</surname><given-names>C</given-names></name><name><surname>Migliorini</surname><given-names>P</given-names></name><name><surname>Balsa</surname><given-names>A</given-names></name><name><surname>Westhovens</surname><given-names>R</given-names></name><name><surname>Barrera</surname><given-names>P</given-names></name><name><surname>Alves</surname><given-names>H</given-names></name><name><surname>Vaz</surname><given-names>C</given-names></name><name><surname>Fernandes</surname><given-names>M</given-names></name><name><surname>Pascual-Salcedo</surname><given-names>D</given-names></name><name><surname>Bombardieri</surname><given-names>S</given-names></name><name><surname>Dequeker</surname><given-names>J</given-names></name><name><surname>Radstake</surname><given-names>TR</given-names></name><name><surname>Van Riel</surname><given-names>P</given-names></name><name><surname>Putte</surname><given-names>L van de</given-names></name><name><surname>Lopes-Vaz</surname><given-names>A</given-names></name><name><surname>Glikmans</surname><given-names>E</given-names></name><name><surname>Barbet</surname><given-names>S</given-names></name><name><surname>Lasbleiz</surname><given-names>S</given-names></name><name><surname>Lemaire</surname><given-names>I</given-names></name><name><surname>Quillet</surname><given-names>P</given-names></name><name><surname>Hilliquin</surname><given-names>P</given-names></name><name><surname>Teixeira</surname><given-names>VH</given-names></name><name><surname>Petit-Teixeira</surname><given-names>E</given-names></name><name><surname>Mbarek</surname><given-names>H</given-names></name><name><surname>Prum</surname><given-names>B</given-names></name><name><surname>Bardin</surname><given-names>T</given-names></name><name><surname>Cornelis</surname><given-names>F</given-names></name><article-title>The ITGAV rs3738919-C allele is associated with rheumatoid arthritis in the European Caucasian population: a family-based study</article-title><source>Arthritis Res Ther</source><year>2007</year><volume>9</volume><fpage>R63</fpage><pub-id pub-id-type="doi">10.1186/ar2221</pub-id><pub-id pub-id-type="pmid">17615072</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Ahnert</surname><given-names>P</given-names></name><name><surname>Kirsten</surname><given-names>H</given-names></name><article-title>Association of ITGAV supports a role of angiogenesis in rheumatoid arthritis</article-title><source>Arthritis Res Ther</source><year>2007</year><volume>9</volume><fpage>108</fpage><pub-id pub-id-type="doi">10.1186/ar2313</pub-id><pub-id pub-id-type="pmid">18001496</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Arnett</surname><given-names>FC</given-names></name><name><surname>Edworthy</surname><given-names>SM</given-names></name><name><surname>Bloch</surname><given-names>DA</given-names></name><name><surname>McShane</surname><given-names>DJ</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><name><surname>Cooper</surname><given-names>NS</given-names></name><name><surname>Healey</surname><given-names>LA</given-names></name><name><surname>Kaplan</surname><given-names>SR</given-names></name><name><surname>Liang</surname><given-names>MH</given-names></name><name><surname>Luthra</surname><given-names>HS</given-names></name><name><surname>Medgser</surname><given-names>TA</given-names></name><name><surname>Mitchell</surname><given-names>DM</given-names></name><name><surname>Neustadt</surname><given-names>DH</given-names></name><name><surname>Pinals</surname><given-names>RS</given-names></name><name><surname>Schaller</surname><given-names>JG</given-names></name><name><surname>Sharp</surname><given-names>JT</given-names></name><name><surname>Wilder</surname><given-names>RL</given-names></name><name><surname>Hunde</surname><given-names>GG</given-names></name><article-title>The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>1988</year><volume>31</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1002/art.1780310302</pub-id><pub-id pub-id-type="pmid">3358796</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Marchini</surname><given-names>J</given-names></name><name><surname>Howie</surname><given-names>B</given-names></name><name><surname>Myers</surname><given-names>S</given-names></name><name><surname>McVean</surname><given-names>G</given-names></name><name><surname>Donnelly</surname><given-names>P</given-names></name><article-title>A new multipoint method for genome-wide association studies by imputation of genotypes</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>906</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1038/ng2088</pub-id><pub-id pub-id-type="pmid">17572673</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Shi</surname><given-names>YY</given-names></name><name><surname>He</surname><given-names>L</given-names></name><article-title>SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci</article-title><source>Cell Res</source><year>2005</year><volume>15</volume><fpage>97</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1038/sj.cr.7290286</pub-id><pub-id pub-id-type="pmid">15740637</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><collab>The Wellcome Trust Case Control Consortium</collab><article-title>Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls</article-title><source>Nature</source><year>2007</year><volume>447</volume><fpage>661</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1038/nature05911</pub-id><pub-id pub-id-type="pmid">17554300</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="other"><article-title>The R Project for Statistical Computing</article-title><ext-link ext-link-type="uri" xlink:href="http://www.r-project.org">http://www.r-project.org</ext-link></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="other"><article-title>International HapMap Project</article-title><ext-link ext-link-type="uri" xlink:href="http://hapmap.ncbi.nlm.nih.gov">http://hapmap.ncbi.nlm.nih.gov</ext-link></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Iikuni</surname><given-names>N</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Ikari</surname><given-names>K</given-names></name><name><surname>Tomatsu</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>M</given-names></name><name><surname>Yamanaka</surname><given-names>H</given-names></name><name><surname>Kamatani</surname><given-names>N</given-names></name><name><surname>Momohara</surname><given-names>S</given-names></name><article-title>ITGAV polymorphism and disease susceptibility in a Japanese rheumatoid arthritis population</article-title><source>Arthritis Res Ther</source><year>2007</year><volume>9</volume><fpage>405</fpage><pub-id pub-id-type="doi">10.1186/ar2303</pub-id><pub-id pub-id-type="pmid">17980054</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Takeuchi</surname><given-names>F</given-names></name><name><surname>Nakano</surname><given-names>K</given-names></name><name><surname>Matsuta</surname><given-names>K</given-names></name><name><surname>Nabeta</surname><given-names>H</given-names></name><name><surname>Bannai</surname><given-names>M</given-names></name><name><surname>Tanimoto</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><article-title>Positive and negative association of HLA-DR genotypes with Japanese rheumatoid arthritis</article-title><source>Clin Exp Rheumatol</source><year>1996</year><volume>14</volume><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">8697652</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>MacGregor</surname><given-names>A</given-names></name><name><surname>Ollier</surname><given-names>W</given-names></name><name><surname>Thomson</surname><given-names>W</given-names></name><name><surname>Jawaheer</surname><given-names>D</given-names></name><name><surname>Silman</surname><given-names>A</given-names></name><article-title>HLA-DRB1*0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity</article-title><source>J Rheumatol</source><year>1995</year><volume>22</volume><fpage>1032</fpage><lpage>1036</lpage><pub-id pub-id-type="pmid">7674226</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Ikari</surname><given-names>K</given-names></name><name><surname>Momohara</surname><given-names>S</given-names></name><name><surname>Inoue</surname><given-names>E</given-names></name><name><surname>Tomatsu</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>M</given-names></name><name><surname>Yamanaka</surname><given-names>H</given-names></name><name><surname>Kamatani</surname><given-names>N</given-names></name><article-title>Haplotype analysis revealed no association between the PTPN22 gene and RA in a Japanese population</article-title><source>Rheumatology (Oxford)</source><year>2006</year><volume>45</volume><fpage>1345</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kel169</pub-id><pub-id pub-id-type="pmid">16690758</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Matsushita</surname><given-names>M</given-names></name><name><surname>Tsuchiya</surname><given-names>N</given-names></name><name><surname>Shiota</surname><given-names>M</given-names></name><name><surname>Komata</surname><given-names>T</given-names></name><name><surname>Matsuta</surname><given-names>K</given-names></name><name><surname>Zama</surname><given-names>K</given-names></name><name><surname>Oka</surname><given-names>T</given-names></name><name><surname>Juji</surname><given-names>T</given-names></name><name><surname>Yamane</surname><given-names>A</given-names></name><name><surname>Tokunaga</surname><given-names>K</given-names></name><article-title>Lack of a strong association of CTLA-4 exon 1 polymorphism with the susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese: an association study using a novel variation screening method</article-title><source>Tissue Antigens</source><year>1999</year><volume>54</volume><fpage>578</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1034/j.1399-0039.1999.540607.x</pub-id><pub-id pub-id-type="pmid">10674972</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Suzuki</surname><given-names>A</given-names></name><name><surname>Yamada</surname><given-names>R</given-names></name><name><surname>Chang</surname><given-names>X</given-names></name><name><surname>Tokuhiro</surname><given-names>S</given-names></name><name><surname>Sawada</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Nagasaki</surname><given-names>M</given-names></name><name><surname>Nakayama-Hamada</surname><given-names>M</given-names></name><name><surname>Kawaida</surname><given-names>R</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name><name><surname>Ohtsuki</surname><given-names>M</given-names></name><name><surname>Furukawa</surname><given-names>H</given-names></name><name><surname>Yoshino</surname><given-names>S</given-names></name><name><surname>Yukioka</surname><given-names>M</given-names></name><name><surname>Tohma</surname><given-names>S</given-names></name><name><surname>Matsubara</surname><given-names>T</given-names></name><name><surname>Wakitani</surname><given-names>S</given-names></name><name><surname>Teshima</surname><given-names>R</given-names></name><name><surname>Nishioka</surname><given-names>Y</given-names></name><name><surname>Sekine</surname><given-names>A</given-names></name><name><surname>Iida</surname><given-names>A</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Tsunoda</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><article-title>Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis</article-title><source>Nat Genet</source><year>2003</year><volume>34</volume><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1038/ng1206</pub-id><pub-id pub-id-type="pmid">12833157</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Ikari</surname><given-names>K</given-names></name><name><surname>Kuwahara</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Momohara</surname><given-names>S</given-names></name><name><surname>Hara</surname><given-names>M</given-names></name><name><surname>Yamanaka</surname><given-names>H</given-names></name><name><surname>Tomatsu</surname><given-names>T</given-names></name><name><surname>Kamatani</surname><given-names>N</given-names></name><article-title>Association between PADI4 and rheumatoid arthritis: a replication study</article-title><source>Arthritis Rheum</source><year>2005</year><volume>52</volume><fpage>3054</fpage><lpage>3057</lpage><pub-id pub-id-type="doi">10.1002/art.21309</pub-id><pub-id pub-id-type="pmid">16200584</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Barton</surname><given-names>A</given-names></name><name><surname>Bowes</surname><given-names>J</given-names></name><name><surname>Eyre</surname><given-names>S</given-names></name><name><surname>Spreckley</surname><given-names>K</given-names></name><name><surname>Hinks</surname><given-names>A</given-names></name><name><surname>John</surname><given-names>S</given-names></name><name><surname>Worthington</surname><given-names>J</given-names></name><article-title>A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population</article-title><source>Arthritis Rheum</source><year>2004</year><volume>50</volume><fpage>1117</fpage><lpage>1121</lpage><pub-id pub-id-type="pmid">15077293</pub-id><pub-id pub-id-type="doi">10.1002/art.20169</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Caponi</surname><given-names>L</given-names></name><name><surname>Petit-Teixeira</surname><given-names>E</given-names></name><name><surname>Sebbag</surname><given-names>M</given-names></name><name><surname>Bongiorni</surname><given-names>F</given-names></name><name><surname>Moscato</surname><given-names>S</given-names></name><name><surname>Pratesi</surname><given-names>F</given-names></name><name><surname>Pierlot</surname><given-names>C</given-names></name><name><surname>Osorio</surname><given-names>J</given-names></name><name><surname>Chapuy-Regaud</surname><given-names>S</given-names></name><name><surname>Guerrin</surname><given-names>M</given-names></name><name><surname>Cornelis</surname><given-names>F</given-names></name><name><surname>Serre</surname><given-names>G</given-names></name><name><surname>Migliorini</surname><given-names>P</given-names></name><article-title>A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population</article-title><source>Ann Rheum Dis</source><year>2005</year><volume>64</volume><fpage>587</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1136/ard.2004.026831</pub-id><pub-id pub-id-type="pmid">15485997</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Kochi</surname><given-names>Y</given-names></name><name><surname>Yamada</surname><given-names>R</given-names></name><name><surname>Suzuki</surname><given-names>A</given-names></name><name><surname>Harley</surname><given-names>JB</given-names></name><name><surname>Shirasawa</surname><given-names>S</given-names></name><name><surname>Sawada</surname><given-names>T</given-names></name><name><surname>Bae</surname><given-names>SC</given-names></name><name><surname>Tokuhiro</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>X</given-names></name><name><surname>Sekine</surname><given-names>A</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Tsunoda</surname><given-names>T</given-names></name><name><surname>Ohnishi</surname><given-names>Y</given-names></name><name><surname>Kaufman</surname><given-names>KM</given-names></name><name><surname>Kang</surname><given-names>CP</given-names></name><name><surname>Kang</surname><given-names>C</given-names></name><name><surname>Otsubo</surname><given-names>S</given-names></name><name><surname>Yumura</surname><given-names>W</given-names></name><name><surname>Mimori</surname><given-names>A</given-names></name><name><surname>Koike</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Sasazuki</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><article-title>A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>478</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1038/ng1540</pub-id><pub-id pub-id-type="pmid">15838509</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Ikari</surname><given-names>K</given-names></name><name><surname>Momohara</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>M</given-names></name><name><surname>Yamanaka</surname><given-names>H</given-names></name><name><surname>Tomatsu</surname><given-names>T</given-names></name><name><surname>Kamatani</surname><given-names>N</given-names></name><article-title>Supportive evidence for a genetic association of the FCRL3 promoter polymorphism with rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><year>2006</year><volume>65</volume><fpage>671</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1136/ard.2005.043489</pub-id><pub-id pub-id-type="pmid">16176992</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Thabet</surname><given-names>MM</given-names></name><name><surname>Wesoly</surname><given-names>J</given-names></name><name><surname>Slagboom</surname><given-names>PE</given-names></name><name><surname>Toes</surname><given-names>RE</given-names></name><name><surname>Huizinga</surname><given-names>TW</given-names></name><article-title>FCRL3 promoter 169 CC homozygosity is associated with susceptibility to rheumatoid arthritis in Dutch Caucasians</article-title><source>Ann Rheum Dis</source><year>2007</year><volume>66</volume><fpage>803</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1136/ard.2006.064949</pub-id><pub-id pub-id-type="pmid">17179172</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Eyre</surname><given-names>S</given-names></name><name><surname>Bowes</surname><given-names>J</given-names></name><name><surname>Potter</surname><given-names>C</given-names></name><name><surname>Worthington</surname><given-names>J</given-names></name><name><surname>Barton</surname><given-names>A</given-names></name><article-title>Association of the FCRL3 gene with rheumatoid arthritis: a further example of population specificity?</article-title><source>Arthritis Res Ther</source><year>2006</year><volume>8</volume><fpage>R117</fpage><pub-id pub-id-type="doi">10.1186/ar2006</pub-id><pub-id pub-id-type="pmid">16859508</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Owen</surname><given-names>CJ</given-names></name><name><surname>Kelly</surname><given-names>H</given-names></name><name><surname>Eden</surname><given-names>JA</given-names></name><name><surname>Merriman</surname><given-names>ME</given-names></name><name><surname>Pearce</surname><given-names>SH</given-names></name><name><surname>Merriman</surname><given-names>TR</given-names></name><article-title>Analysis of the Fc receptor-like-3 (FCRL3) locus in Caucasians with autoimmune disorders suggests a complex pattern of disease association</article-title><source>J Clin Endocrinol Metab</source><year>2007</year><volume>92</volume><fpage>1106</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1210/jc.2006-2183</pub-id><pub-id pub-id-type="pmid">17200162</pub-id></mixed-citation></ref></ref-list></back></article>